Waist Circumference Independently Associated with Breast Cancer Risk
the Cancer Therapy Advisor take:
Overall adiposity was positively associated with overall breast cancer risk — specifically waist circumference with overall risk in premenopausal and postmenopausal women, according to an article published online in the journal Cancer.
Participants enrolled in the study from 2003 to 2009 included a total of 50,884 women in a Sister Study cohort (aged 35 to 74 years).
In order to be eligible to participate, the women must have had a sister previously diagnosed with breast cancer.
Results showed 2,009 breast cancer diagnoses were made during the follow-up period (mean=5.4 years). Overall breast cancer risk had positive associations with weight, body mass index (BMI), waist circumference, and waist-to-hip ratio.
Hazard ratios (HR) for these associations were greater among postmenopausal women, women with hormonally responsive tumors, and those not currently using postmenopausal hormones.
Furthermore, waist circumference correlations continued to be present after adjusting for BMI in both postmenopausal women (81-88 cm vs. ≤80 cm: HR = 1.16; 95% CI: 1.01, 1.35 and >88 cm vs. ≤80 cm: HR = 1.30; 95% CI: 1.10, 1.54) and premenopausal women (81-88 cm vs. ≤80 cm: HR = 1.56; 95% CI: 1.19, 2.04 and >88 cm vs. ≤80 cm: HR = 1.30; 95% CI: 0.91, 1.87).
Overall adiposity was positively associated with overall breast cancer risk in premenopausal and postmenopausal women.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Long-term Survival From Ipilimumab/Nivolumab Combination in Metastatic Melanoma
- Radiation Therapy Increases 5-year Rate of Cardiac Events in Small-cell Lung Cancer
- Questions Remain for First-line Treatment Selection and Sequencing in Advanced Melanoma
- Pazopanib: Where Does It Stand as Adjuvant Therapy in Localized RCC?
- Repeat T790M Testing Recommended for TKI-resistant Patients With NSCLC
- Affordable Care Act Linked to Lower Rates of Cancer Diagnosis Among Uninsured
- FDA Approves Axicabtagene Ciloleucel for Non-Hodgkin Lymphoma, Questions Remain About Cost and Toxicity
- PAK Inhibition Could Abrogate MAPK Inhibitor Resistance in BRAF-mutant Melanoma
- Lung Cancer Treatment in North America: Recent Advances and Future Promises
- Atezolizumab Maintains Clinical Benefit After 2 Years in Advanced NSCLC